Arbutus to Discontinue its P-Ia/Ib Clinical Study of AB-506 to Treat Patients with Chronic Hepatitis B

Arbutus to Discontinue its P-Ia/Ib Clinical Study of AB-506 for Treatment of Chronic Hepatitis B

Shots:

  • Arbutus discontinues its P-Ia/Ib study of AB-506 due to disappointing clinical findings i.e, observation of two cases of acute hepatitis in P-Ia clinical study assessing Ab-506 in healthy volunteers for 28days
  • Following the results of P-Ia/Ib study, Abratus drop its plan to initiate combination study of AB-506 and AB-729 in H2’20 and will present the results of P-Ia/Ib study in details regarding the two cases of acute hepatitis
  • AB-506 is an oral HBV capsid inhibitor, being evaluated for the treatment of chronic hepatitis B while AB-729 is an RNA interference (RNAi) therapeutic targeted to hepatocytes utilizing Arbutus’ novel GalNAc delivery technology enabling SC administration with expected monthly dosing

Click here to­ read full press release/ article | Ref: Arbutus | Image: BC Technology